Clinical trials: Soft Tissue Sarcomas
Hypereosinophilic Syndrome, Systemic Mastocytosis
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
This trial is for various types of malignancies which may depend on certain enzymes (tyrosine kinases) for growth. The objective of this study is to assess to what extent imatinib mesylate blocks these enzymes and to assess the…
- Conditions
- Hypereosinophilic Syndrome, Systemic Mastocytosis, Chronic Myelomonocytic Leukemia, Dermatofibrosarcoma
- Trial name
- NCT00171912
- Testing
- imatinib mesylate
- Where
- Australia
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Sarcoma, Bone Tumor
Cost-effectiveness Evaluation of the Use of a Patient Specific Instrument for Surgical Resection of Malignant Bone Tumor Within the Pelvis Versus the Conventional Surgical Treatment
Primitive malignant bone tumor or mixt tumor (compounded of soft tissues and bone) is a rare pathology particularly within the pelvis, the sacrum or the hip (between 25 and 80 new cases in France per year).
- Trial name
- MARGIC (NCT02544711)
- Testing
- Patient specific instrument, Conventional surgical treatment
- Where
- 8 sites in France
- Volunteers
- 88 people
- Sponsor
- Nantes University Hospital
Breast Cancer, Non-small Cell Lung Cancer
BostonGene and Exigent Genomic INsight Study
The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients.
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma
- Trial name
- BEGIN (NCT06272864)
- Where
- 7 sites in United States
- Volunteers
- 400 people
- Sponsor
- BostonGene
Sarcoma, Soft Tissue Sarcoma
Cathepsin Activatable Fluorescent Probe
Real-time detection of cancer cells during surgical removal of a tumor is important. Currently when tissue is removed at the time of surgery, the removed tissue goes to pathology when the margins (edges of the tissue) are…
- Conditions
- Sarcoma, Soft Tissue Sarcoma, Breast Cancer
- Trial name
- LUM015 (NCT01626066)
- Testing
- LUM015
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- David Kirsch
Sarcoma
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
The purpose of this study is to study normal and sarcoma cells. To study these cells we need to have human tissue. You will be having or have already had a procedure to remove tissue. We would like to use some of this tissue.
- Trial name
- NCT00579566
- Testing
- Specimen protocol
- Where
- 7 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adults Treated During Childhood or Adolescence for a Malignant Bone Tumor (Osteosarcoma and Ewing Sarcoma)
Long Term Brain Toxicity of Chemotherapy in Patients Treated for a Bone TumorDuring Childhood or Adolescence
To assess the neurocognitive outcomes in patients treated with chemotherapy for a malignant bone tumor during childhood and adolescence and the factors associated with neurocognitive impairment and/or complaints
- Trial name
- OSE (NCT05071001)
- Testing
- MRI
- Where
- France
- Volunteers
- 92 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
This phase III trial studies how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has…
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma
- Trial name
- NCT03914612
- Testing
- Carboplatin, Computed Tomography, Paclitaxel
- Where
- 397 sites in United States, Canada and 3 more
- Volunteers
- 813 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
Swiss Sarcoma Network: Prediction Model for Patient Selection in Sarcoma Care
The primary significance of this project is to perform a detailed analysis to assess the diagnostics, treatment and follow-up care, to develop a prediction model for future patient selection regarding various diagnostic and…
- Trial name
- NCT04300257
- Where
- 8 sites in Switzerland
- Volunteers
- 600 people
- Sponsor
- Kantonsspital Winterthur KSW
Sarcoma
Establishment of a Prospective Clinical-biological Database
A Clinical and Biological Database will provide to the scientific community a collection of blood and tissues with clinical data to improve knowledge about cancer and help to develope new cancer treatments.
- Trial name
- BCBSarcome (NCT04458792)
- Testing
- Paraffin tissue samples, blood sample
- Where
- France
- Volunteers
- 450 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Sarcoma
Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood.
- Trial name
- NCT00027911
- Testing
- NY-ESO-1 peptide vaccine, sargramostim
- Where
- United States
- Sponsor
- Columbia University
Refractory and/or Relapsed Metastatic Solid Tumors
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk…
- Trial name
- NCT01804634
- Testing
- Cyclophosphamide, Fludarabine, low dose total body irradiation
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma
Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma
The objective of the trial is to assess the efficacy of Durvalumab and Tremelimumab in comparison to doxorubicin in treatment-naïve Soft tissue sarcoma patients
- Trial name
- MEDISARC (NCT03317457)
- Testing
- Durvalumab and Tremelimumab, Doxorubicin
- Where
- Germany
- Volunteers
- 103 people
- Sponsor
- AIO-Studien-gGmbH
Sarcoma
Combination Chemotherapy in Treating Patients With Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002492
- Testing
- cisplatin, doxorubicin hydrochloride, isolated limb perfusion
- Where
- United States
- Sponsor
- University of Miami
Solid Tumors, Neuroblastoma
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
A pilot pharmacokinetic trial to determine the safety and efficacy of a flavored, orally administered irinotecan VAL-413 (Orotecan®) given with temozolomide for treatment of recurrent pediatric solid tumors including but not…
- Conditions
- Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma
- Trial name
- NCT04337177
- Testing
- VAL-413, Temozolomide
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- Valent Technologies, LLC
Sarcoma, Leiomyosarcoma
Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)
The purpose of this study is to see the effects, good and/or bad, of the drug combination of gemcitabine, docetaxel and pazopanib on sarcoma. This is a phase Ib-phase II clinical trial.
- Conditions
- Sarcoma, Leiomyosarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Fibrous
- Trial name
- NCT01418001
- Testing
- Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ewing's Sarcoma, Osteosarcoma
HGS-ETR2 to Treat Children With Solid Tumors
Background HGS-ETR2 is a monoclonal antibody, produced in the laboratory from human genes. HGS-ETR2 targets a protein called the TRAIL receptor that is located on the surface of some tumor cells.
- Conditions
- Ewing's Sarcoma, Osteosarcoma, Neuroblastoma, Rhabdomyosarcoma
- Trial name
- NCT00428272
- Testing
- Lexatumumab alone, Lexatumumab in combination, Interferon gamma 1b in combination
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Myxofibrosarcoma, Recurrent Adult Soft Tissue Sarcoma
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
This phase II trial studies how well alisertib works in treating patients with sarcoma that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has spread to other places…
- Conditions
- Myxofibrosarcoma, Recurrent Adult Soft Tissue Sarcoma, Recurrent Leiomyosarcoma, Recurrent Liposarcoma
- Trial name
- NCT01653028
- Testing
- Alisertib, Laboratory Biomarker Analysis
- Where
- 235 sites in United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Cardiac Toxicity, Sarcoma
Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy before surgery may shrink the tumor so that it can be removed during surgery.
- Trial name
- NCT00019864
- Testing
- filgrastim, cisplatin, dexrazoxane hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma
Enhanced Recovery After Surgery in Extremity Sarcoma
The purpose of this study is to demonstrate the efficacy of implementing the enhanced recovery after surgery (ERAS) pathway in a prospective manner to patients undergoing surgical treatment for extremity sarcoma.
- Trial name
- NCT04461171
- Testing
- Enhanced Recovery After Surgery
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Joshua Lawrenz